Before Wegovy, 190,000 people in the U.S. were claiming GLP-1 drugs ... with 5.1 percent of white patients with obesity on weight loss drugs compared to just 3.7 percent of Hispanic patients with ...
Zealand Pharma A/S said moderate doses of its experimental weight-loss drug helped patients pare pounds with less nausea than ...
The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic ...
Novo Nordisk ( NVO, Financials) entered an exclusive agreement with Ascendis Pharma ( ASND, Financials) to license Ascendis's TransCon technology platform for developing novel treatments targeting ...
Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...
A study noted an average weight loss of 17.6% with Allurion’s device in patients who had no or less than 5% weight loss with ...
Related Why treatments can fail patients with 'wet' macular degeneration Ozempic, Wegovy might help ease knee arthritis pain ...
Related Ozempic, Wegovy might help ease knee arthritis pain Weight-loss surgeries decline 25% as GLP-1 drugs grow in popularity Ozempic, Wegovy might lower Alzheimer's risk in Type 2 diabetics But GLP ...
Wegovy — the weight loss version of the drug Ozempic — was approved by the U.S. Food and Drug Administration in 2021. It was ...
As demand for popular weight-loss drugs like Wegovy and Zepbound skyrockets, patients are taking dosage amounts into their ...
21hon MSN
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback